Mitchel L. Zoler, PhD

News

Low copays drive better adherence to new diabetes drugs

Author:: Mitchel L. Zoler, PhD

Publish date: June 22, 2023

Regardless of patients’ socioeconmic status, copays were related to adherence.

News

BMI ‘vastly underestimates’ true obesity

Author:: Mitchel L. Zoler, PhD

Publish date: June 19, 2023

“We’re at the start of the end of BMI.”

News

Anabolic-steroid withdrawal regimens show promise in men

Author:: Mitchel L. Zoler, PhD

Publish date: June 16, 2023

“There is a vacuum of medical advice on what to do” when men stop taking steroids.

News

Troponin to ID diabetes patients with silent heart disease?

Author:: Mitchel L. Zoler, PhD

Publish date: May 31, 2023

“What we are seeing is that many people with type 2 diabetes who have not had a heart attack or a history of cardiovascular disease are at high ris...

News

FDA approves new drug, sotagliflozin, for heart failure

Author:: Mitchel L. Zoler, PhD

Publish date: May 30, 2023

“It will be a reasonably tall task for sotagliflozin to come from behind and be disruptive in a space where there are already two well-established ...

News

CKD Screening in all U.S. adults found cost effective

Author:: Mitchel L. Zoler, PhD

Publish date: May 22, 2023

Modeling showed screening for and treating chronic kidney disease in U.S. adults was cost effective now that SGLT2 inhibitors are available.

News

Tirzepatide scores win in second obesity trial, SURMOUNT-2

Author:: Mitchel L. Zoler, PhD

Publish date: April 27, 2023

Tirzepatide (Mounjaro) met its primary endpoints, compared with placebo, in the SURMOUNT-2 trial, designed to test weight-loss efficacy, in top-lin...

News

BMI is a flawed measure of obesity. What are alternatives?

Author:: Mitchel L. Zoler, PhD

Publish date: April 26, 2023

“BMI is trash. Full stop.”

News

Dapagliflozin’s HFpEF benefit tied to lower filling pressure

Author:: Mitchel L. Zoler, PhD

Publish date: March 23, 2023

Patients with HFpEF who took dapagliflozin significantly cut their pulmonary capillary wedge pressures, a likely ...

News

‘Unheard of’ PAH improvement with novel drug: STELLAR

Author:: Mitchel L. Zoler, PhD

Publish date: March 13, 2023

Sotatercept, a designer molecule that removes a key driver of pulmonary arterial hypertension, had efficacy and safety in the first of three pivota...

News

Can SGLT2 inhibitors limit acute kidney injury in type 2 diabetes?

Author:: Mitchel L. Zoler, PhD

Publish date: March 10, 2023

Contrary to the initial concerns that SGLT2 inhibitors might increase the risk of acute kidney injury, new data indicate that this complication is ...